Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-87704916 |
| Synonyms | |
| Therapy Description |
JNJ-87704916 is a recombinant oncolytic herpes simplex virus type 1 (HSV-1), which potentially induces tumor cell lysis and an antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-87704916 | JNJ87704916|JNJ 87704916 | JNJ-87704916 is a recombinant oncolytic herpes simplex virus type 1 (HSV-1), which potentially induces tumor cell lysis and an antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06311578 | Phase I | JNJ-87704916 Cetrelimab + JNJ-87704916 | A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | CAN | 0 |